Order Article Reprints

Li T, Xu Y, Sun W, Yan W, Wang C, Hu T, Zhang X, Luo Z, Liu X, Chen Y. Adjuvant Anti-PD-1 Immunotherapy versus Conventional Therapy for Stage III Melanoma: A Real-World Retrospective Cohort Study. Pharmaceuticals. 2023; 16(1):41. https://doi.org/10.3390/ph16010041

Li, Tong, Yu Xu, Wei Sun, Wangjun Yan, Chunmeng Wang, Tu Hu, Xiaowei Zhang, Zhiguo Luo, Xin Liu, and Yong Chen. 2023. "Adjuvant Anti-PD-1 Immunotherapy versus Conventional Therapy for Stage III Melanoma: A Real-World Retrospective Cohort Study" Pharmaceuticals 16, no. 1: 41. https://doi.org/10.3390/ph16010041

Li, T., Xu, Y., Sun, W., Yan, W., Wang, C., Hu, T., Zhang, X., Luo, Z., Liu, X., & Chen, Y. (2023). Adjuvant Anti-PD-1 Immunotherapy versus Conventional Therapy for Stage III Melanoma: A Real-World Retrospective Cohort Study. Pharmaceuticals, 16(1), 41. https://doi.org/10.3390/ph16010041